UNSPSC 51111907: Sodium phenylbutyrate

This classification denotes a phenylbutyrate and antineoplastic agent with the molecular formula C10H11O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NT6K61736T, chemically known as benzenebutanoic acid, sodium salt but generally known as sodium phenylbutyrate, which bears US NIH Compound Identifier 15585. European Medicines Agency schedules Sodium phenylbutyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12586MIG.

World Health Organization schedules sodium phenylbutyrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SODIUM PHENYLBUTYRATE remains the US FDA Preferred Term for this commodity. Sodium phenylbutyrate bears US NLM identifiers UMLS ID C0718066 and NCI Concept Code C1440. SMILES: C1=CC=C(C=C1)CCCC(=O)[O-].[NA+].

UNSPSC 51111907 Sodium phenylbutyrate is a Commodity code that represents a specific pharmaceutical product used in the treatment of urea cycle disorders and related metabolic conditions. State and local procurement activity under this code centers on pharmaceutical procurement by state health and human services agencies managing Medicaid and employee health plans. The issuing bodies soliciting under this code are primarily state health departments and health and human services commissions that administer pharmacy benefit programs for beneficiary populations.

The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI, with a response deadline of April 3, 2026, solicits information from potential vendors regarding their capacity to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, bypassing traditional pharmacy benefit managers, group purchasing organizations, and wholesalers. The procurement seeks vendor experience with direct contracting for self-insured employers and health plans within the past two years, flexibility to negotiate contracts using net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. No award value or budget range was identified in the RFI materials; the state characterized this as a preliminary information-gathering phase to inform future formal solicitations and procurement strategy before issuing a subsequent Request for Proposal with established financial and temporal parameters.